Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC)

1.50
Delayed Data
As of Sep 30
 +0.18 / +13.64%
Today’s Change
1.01
Today|||52-Week Range
5.85
-61.44%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$18.3M

Company Description

Cyclacel Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It uses cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. The company builds a biopharmaceutical business, which is focused in hematology and oncology based on a pipeline of novel drug candidates. Its products include CYC065, seliciclib, and sapacitabine. The company was founded by Ronald J. Berenson, David Philip Lane, and David Glover on August 13, 1996 and is headquartered in Berkeley Heights, NJ.

Contact Information

Cyclacel Pharmaceuticals, Inc.
200 Connell Drive
Berkeley Heights New Jersey 07922
P:(908) 517-7330
Investor Relations:
1908

Employees

Shareholders

Other institutional20.10%
Mutual fund holders1.88%
Individual stakeholders1.73%

Top Executives

Spiro RombotisPresident, Chief Executive Officer & Director
Paul McBarronSecretary, Chief Operating & Financial Officer
Mark KirschbaumChief Medical Officer & Senior Vice President